"Biogen Shifts Focus Away from Aduhelm, Explores Alternative Alzheimer's Treatments"

Biogen is discontinuing its controversial Alzheimer's drug Aduhelm to focus on other treatments, including its blockbuster drug Leqembi, which was developed with Japan's Eisai and approved in 2023. The decision comes after concerns about the risks of Aduhelm outweighing its benefits, leading Medicare to significantly limit coverage of the drug. Despite discontinuing Aduhelm, Biogen aims to build a leading franchise addressing the multiple pathologies of Alzheimer's disease and patient needs.